New data from BIO-RESORT for treatment of CAD presented at cardiology conference (CRT 2019)
Three-year outcome data from the BIO-RESORT randomized controlled trial were presented at CRT ( interventional cardiology conference) 2019 in a late-breaking clinical trials session by Dr. Clemens von Birgelen, Thoraxcentrum Twente, MST, Enschede, The Netherlands. Results from this large three-arm trial with complex all-comers population treated with three highly dissimilar drug-eluting stents (DES) confirmed the trend of earlier data, supporting the use of the ultrathin bioabsorbable polymer DES Orsiro.
At the three-year follow-up in the BIO-RESORT trial, with a cohort of 3,514 patients, all three stents showed low target vessel failure (TVF) rates. Orsiro demonstrated favorable outcomes without reaching statistical significance (Orsiro 8.5%, Synergy 8.8%, Resolute Integrity 10.0%). The same tendency was observed for target lesion revascularization (TLR) where Orsiro demonstrated numerically lower values in comparison to Resolute Integrity and Synergy DES (Orsiro 2.9%, Synergy 3.3%, Resolute Integrity 3.8%).
Meta-Analysis Shows Significant Reduction in Risk of Myocardial Infarction for Orsiro compared to Xience>:Dr. Thomas Pilgrim, University of Bern, Switzerland, presented the results of a patient-level meta-analysis from four randomized controlled trials comparing the safety and efficacy of Orsiro to Xience. From the pool of 4,480 patients from BIOFLOW-II, -IV, and -V, as well as BIOSCIENCE, 2,630 patients were treated with Orsiro and 1,850 with Xience. The primary endpoint was TLF at maximum duration of follow-up. For the primary endpoint, Orsiro demonstrated a favorable trend without reaching statistical significance in comparison to Xience (11.9% vs. 14.5% respectively). No differences between Orsiro and Xience were seen in the individual components of TLF: Cardiac death occurred in 3.5% vs. 4.5% of the patients, target-vessel myocardial infarction in 5.0% vs. 6.5% and clinically-driven TLR in 5.9% vs. 7.0% for Orsiro and Xience, respectively. While the safety endpoint of definite or probable stent thrombosis did not show a statistical difference between Orsiro and Xience, (2.7% vs. 4.5% respectively), a statistically significant reduction in the risk of any myocardial infarction among patients undergoing PCI with Orsiro in comparison to Xience was observed (7.1% vs. 9.6%, p=0.03).
Lower Medical Costs, Better Patient Outcomes: - Dr. Soeren Mattke, University of Southern California, Los Angeles, California, presented results from the health economic evaluation based on the two-year results of the BIOFLOW-V clinical trial . The evaluation used a Markov simulation to project the mortality and cost outcomes from a US health systems perspective over a horizon of four years and builds on work published in 2018. The findings suggest that the use of the Orsiro stent is associated with a meaningful reduction in direct medical costs and improved patient outcomes compared to the Xience stent. The study estimated cost savings of $2,429 per patient over four years, assuming the two stents were priced at parity. Around two-thirds of the savings were due to the lower rate of spontaneous target vessel myocardial infarction in the first two years after stent implantation. The lower rate of adverse events for the Orsiro stent in the BIOFLOW-V trial is projected to reduce mortality risk by 6% over four years after stent implantation compared to the Xience stent. “Those results may help clinicians, payers and purchasers to make decisions about the choice of coronary stents, as they suggest that the use of the Orsiro stent can simultaneously reduce medical costs and improve patient outcomes. For a high volume procedure like coronary stenting, these differences have meaningful implications for population health and financial sustainability of healthcare systems,” said Dr. Mattke.
Comment: On 22 February 2019 the FDA approved the Orsiro DES for the treatment of coronary artery disease. The ultrathin strut stent is now available for hospitals in the US, which means that interventionalists can rely on Orsiro’s deliverability to treat complex lesions and challenging subgroups.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)